Editas Medicine (EDIT) Other Non-Current Assets (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Other Non-Current Assets of $3.0 million for Q4 2025, down 43.02% year-over-year from $5.2 million in Q4 2024, and little changed quarter-over-quarter from $3.0 million in Q3 2025.
Editas Medicine (EDIT) Other Non-Current Assets (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Other Non-Current Assets for 11 consecutive years, with $3.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Assets fell 43.02% year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $3.0 million (down 43.02% YoY), while the FY2025 annual figure was $3.0 million, down 43.02% from the prior year.
- Other Non-Current Assets held at $3.0 million in Q4 2025 per EDIT's latest filing, from $3.0 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $9.5 million in Q1 2024 and bottomed at $3.0 million in Q4 2025.
- Historically, Other Non-Current Assets has averaged $6.2 million across 5 years, with a median of $6.7 million in 2021.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets soared 179.72% — and 2025, when it slumped 55.75%.
- Editas Medicine's Other Non-Current Assets stood at $6.8 million in 2021, then dropped by 22.87% to $5.3 million in 2022, then surged by 63.49% to $8.6 million in 2023, then tumbled by 39.18% to $5.2 million in 2024, then plunged by 43.02% to $3.0 million in 2025.
- Business Quant data shows EDIT's Other Non-Current Assets at $3.0 million in Q4 2025, $3.0 million in Q3 2025, and $4.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 2.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.98 Mn |
| Sep 30, 2025 | 2.99 Mn |
| Jun 30, 2025 | 4.20 Mn |
| Mar 31, 2025 | 4.20 Mn |
| Dec 31, 2024 | 5.22 Mn |
| Sep 30, 2024 | 5.28 Mn |
| Jun 30, 2024 | 8.15 Mn |
| Mar 31, 2024 | 9.49 Mn |
| Dec 31, 2023 | 8.59 Mn |
| Sep 30, 2023 | 5.76 Mn |
| Jun 30, 2023 | 5.25 Mn |
| Mar 31, 2023 | 6.75 Mn |
| Dec 31, 2022 | 5.25 Mn |
| Sep 30, 2022 | 7.53 Mn |
| Jun 30, 2022 | 7.53 Mn |
| Mar 31, 2022 | 7.32 Mn |
| Dec 31, 2021 | 6.81 Mn |
| Sep 30, 2021 | 6.78 Mn |
| Jun 30, 2021 | 6.78 Mn |
| Mar 31, 2021 | 6.69 Mn |